Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LMDX source : Www.biospace.com save search
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
Published: 2023-03-21 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.06%
H: 6.95%
C: 0.0%
year results
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
Published: 2023-02-06 (Crawled : 16:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 10.0%
H: 0.76%
C: -9.09%
fda covid solutions approval authorization molecular influenza
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test LumiraDx Limited, a next-generation point of care diagnostics company, announced it has receiv...
Published: 2022-12-14 (Crawled : 10:00) - biospace.com/
RLFTF | $1.43 11.45% 3.8K
|
n/a
|
| O: -10.62%
H: 18.77%
C: 5.75%
LMDX | $0.016 -15.0% 130M
|
|
| O: -2.04%
H: 6.22%
C: -4.9%
care ongoing test diagnostics molecular
LumiraDx Reports Third Quarter 2022 ResultsProgress on Near-Term Growth Opportunities and Cost Savings
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.91%
H: 16.16%
C: 11.11%
growth
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
Published: 2022-11-02 (Crawled : 12:20) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 1.01%
H: 5.0%
C: 0.0%
conference financial results
LumiraDx Reports Second Quarter 2022 ResultsStrong Pipeline Progress and Commercialization Priorities for Newly Authorized Products
Published: 2022-08-18 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -5.33%
H: 3.52%
C: -15.49%
authorized commercialization
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
Published: 2022-08-11 (Crawled : 13:20) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.57%
H: 6.21%
C: -3.95%
conference results
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
Published: 2022-06-09 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -1.87%
H: 0.0%
C: -6.67%
covid-19 system test
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
Published: 2022-06-08 (Crawled : 11:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 3.35%
H: 12.22%
C: 6.73%
star sars-cov-2
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
Published: 2022-05-20 (Crawled : 10:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -2.81%
H: 3.95%
C: 1.84%
test sars-cov-2
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
Published: 2022-04-29 (Crawled : 12:20) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.22%
H: 5.26%
C: 4.82%
conference results
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
Published: 2022-03-10 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 8.77%
H: 0.0%
C: -9.25%
report results
LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 2.68%
H: 1.16%
C: -3.48%
financial results conference results
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Published: 2022-01-14 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.0%
H: 2.78%
C: 1.95%
covid-19 covid test
LumiraDx CRP Test Achieves CE Marking
Published: 2022-01-11 (Crawled : 12:30) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -1.95%
H: 4.91%
C: 2.92%
test
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Published: 2021-12-23 (Crawled : 12:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 0.77%
H: 3.92%
C: -2.18%
covid-19 ce mark covid test
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.85%
H: 11.78%
C: 11.17%
sars-cov-2
Audere Receives FDA Emergency Use Authorization for HealthPulse@home COVID-19 Specimen Collection Test Kit
Published: 2021-12-07 (Crawled : 15:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 2.97%
H: 3.74%
C: -2.67%
fda covid authorization test merge covid-19 emergency use authorization
FDA Reissues LumiraDx Fast Lab Solutions' EUA for SARS CoV-2 RNA STAR Complete Molecular Reagents to Allow High Throughput and Asymptomatic Testing Solutions
Published: 2021-12-01 (Crawled : 14:30) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: 8.54%
H: 3.01%
C: -7.67%
fda test molecular sars-cov-2
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
LMDX | $0.016 -15.0% 130M
|
|
| O: -0.23%
H: 6.35%
C: 2.96%
financial results results conference
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.